icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
Voir aussi
Décision d'accès précoce
14/11/2024
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
6cBMdrPthXTsTtK7